Intravenous Labetalol Versus Hydralazine in Preeclampsia

NCT06360601 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-12-02

No results posted yet for this study

Summary

We study the effect of intravenous labetalol versus hydralazine in sever preeclampsia patients on cerebral blood flow and neurological outcome

Conditions

  • Preeclampsia Severe

Interventions

DRUG

Labetalol Injection

Labetalol intravenous infusion 20ml/hr

DRUG

HydrALAZINE Injection

Hydralazine intravenous infusion 5mg/hr

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2024-11-20
Completion
2024-12-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06360601 on ClinicalTrials.gov